Protease-powered precision
Our next-gen CRISPR protease uses stable proteins as reporter substrates, avoiding false positives from nucleases.
Pioneering the next generation of diagnostics
A molecular test for lateral flow assays
GRIP’s diagnostic platform—powered by a CRISPR protease—detects pathogen RNA and amplifies signal in minutes, providing accurate results without nucleic acid amplification.
Molecular-grade performance meets the simplicity of lateral flow.
The next generation of CRISPR diagnostics is here
GRIP’s diagnostic platform is built on a CRISPR protease engine. The tests are fast, operate at room temperature, require no nucleic acid pre-amplification, and are readily adaptable to multiple existing readout formats — delivering molecular-grade accuracy wherever testing is needed.
The GRIP platform at a glance
Results in minutes
Our enzymes rapidly amplify signal and work at room temperature, giving lab-grade results in just minutes.
Pathogen and sample agnostic
Detect bacteria, viruses, or fungi. Saliva, swabs, and urine samples are easily integrated, enabling a variety of sample inputs.
Plug-and-play manufacturing
GRIP’s protein-based reagents allow for seamless integration into proven and robust immunoassay pipelines.
GRIP’s CRISPR protease enzyme
A flexible platform technology
GRIP's platform brings molecular test precision to multiple readout methods, making the technology adaptable to the differing needs of PON and POC diagnostics. Readout methods include lateral flow assays, electrochemical tests, and even simple colorimetric assays.
Closing the gap in point-of-care diagnostics
Point-of-care diagnostics for sexually transmitted infections (STIs), urinary tract infections (UTIs), and upper respiratory infections (URIs) is an over US$2 billion/year global market. And yet, fast, accurate, and affordable testing is difficult to access where it's needed most.
Gold-standard molecular tests like PCR are often centralized, expensive, and slow to deploy. That leaves clinics, urgent care centers, and community health programs without the needed tools to rapidly detect STIs, UTIs, and URIs, and prevent transmission.
GRIP's diagnostic is engineered to bring molecular-grade performance to point-of-need (PON) and point-of-care (POC) settings, helping close the gap between massive testing demand and the need for fast, actionable results.
Michael Osterholm PhD, MPH
University of Minnesota Regents Professor,
McKnight Presidential Endowed Chair in Public Health; Author;
Clinical Advisor, GRIP Molecular Technologies, Inc.
“There is a need for next-generation medical diagnostics that can be performed by anyone, anywhere, at any time, that provide results of a quality only available today via time and resource consuming test methods and equipment. This would position the healthcare system to respond differently to a future pandemic situation. The GRIP team and their collaborators are working to develop this type of innovative diagnostic technology.”
— Michael Osterholm, Ph.D., MPH
Partners & collaborators
